Shanghai Hanchen Xingtai Pharmaceutical Technology

Shanghai Hanchen Xingtai Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery and development of innovative small molecule therapeutics. The company primarily targets oncology and metabolic diseases, leveraging its proprietary drug discovery platform to create high-potency candidates. Its lead program, HC-1102, is a novel androgen receptor antagonist being developed for the treatment of metastatic castration-resistant prostate cancer. Hanchen Xingtai aims to address unmet medical needs through precision medicine and advanced chemical synthesis. The company operates as a key R&D entity within the broader Hanchen Healthcare Group ecosystem.